Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 9:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Peanut Clear all
Completed Phase 1 Interventional

A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

NCT03755713
View directory record Official record
Conditions
Peanut Allergy
Interventions
ASP0892, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Little Rock, Arkansas • Mountain View, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Sep 23, 2026, 9:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Flavanol Absorption, Metabolism and Excretion From Fruit-based Drinks and Other Food Matrixes

NCT03526094
View directory record Official record
Conditions
Healthy
Interventions
Flavanols-capsules, Flavanol-banana blend, Flavanol-high protein drink, Flavanol-berry blend, Flavanol-sports drink, Flavanol-peanut butter toast, Flavanol-oats, Flavanol-yogurt, II- Flavanol drink, II- Flavanol drink + banana blend
Other
Lead sponsor
University of California, Davis
Other
Eligibility
25 Years to 60 Years · Male only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Sep 23, 2026, 9:24 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

NCT03067129
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation
Drug
Lead sponsor
AbbVie
Industry
Eligibility
3 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
15
States / cities
San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 23, 2026, 9:24 PM EDT
Completed Early Phase 1 Interventional

Oral Peanut Immunotherapy for Peanut Allergic Patients

NCT01891136
View directory record Official record
Conditions
Peanut Hypersensitivity
Interventions
Peanut protein
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 16 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Sep 23, 2026, 9:24 PM EDT
Active, not recruiting Phase 3 Interventional

Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)

NCT07003919
View directory record Official record
Conditions
Allergy, Peanut Allergy
Interventions
DBV712 250 mcg, Placebo
Combination Product
Lead sponsor
DBV Technologies
Industry
Eligibility
1 Year to 3 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
56
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 23, 2026, 9:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Atopic Dermatitis (AD) and Food Allergy

NCT03168113
View directory record Official record
Conditions
Atopic Dermatitis (AD), Non-atopic Healthy Controls
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 17 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 23, 2026, 9:24 PM EDT
Not yet recruiting Not applicable Interventional

Cardiometabolic & Cognitive Effects of Peanut Butter in Prediabetes

NCT07714096
View directory record Official record
Conditions
Prediabetes
Interventions
Peanut butter, Usual diet
Other
Lead sponsor
Penn State University
Other
Eligibility
40 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 23, 2026, 9:24 PM EDT
Recruiting Phase 2Phase 3 Interventional

Anticholinergics for Cervical Edema in Labor

NCT06702670
View directory record Official record
Conditions
Labor Dystocia
Interventions
Treatment with Diphenhydramine, Usual Care
Drug · Combination Product
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 23, 2026, 9:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance

NCT01373242
View directory record Official record
Conditions
Peanut Hypersensitivity, Food Hypersensitivity, Food Allergy, Peanut Allergy
Interventions
Liquid peanut extract (Peanut SLIT)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 12 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Sep 23, 2026, 9:24 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Cardiometabolic Effects of the Recommended Daily Pecan Intake Dose

NCT07696403
View directory record Official record
Conditions
Nutrition, Healthy, Dyslipidemia, Overweight and Obesity
Interventions
Pecan, Control
Other
Lead sponsor
University of Georgia
Other
Eligibility
25 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2030
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 23, 2026, 9:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults

NCT04015479
View directory record Official record
Conditions
Aging, Sarcopenia
Interventions
Peanut Protein Powder, Full body resistance training
Dietary Supplement · Behavioral
Lead sponsor
Auburn University
Other
Eligibility
50 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Sep 23, 2026, 9:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Tolerance Following Peanut Oral Immunotherapy

NCT01750879
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut Flour, Oat Flour
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Sep 23, 2026, 9:24 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effect of Dry Roasted Peanuts and Boiled Peanuts on Glycemic Control

NCT04171648
View directory record Official record
Conditions
Diabetes Mellitus, Glycemic Control
Interventions
Roasted Peanut Treatment, Boiled Peanut Treatment
Other
Lead sponsor
North Carolina State University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 23, 2026, 9:24 PM EDT
Terminated Phase 1 Interventional

CNP-201 in Subjects With Peanut Allergy

NCT05250856
View directory record Official record
Conditions
Peanut Allergy
Interventions
CNP-201, Placebo
Drug
Lead sponsor
COUR Pharmaceutical Development Company, Inc.
Industry
Eligibility
16 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
17
States / cities
Birmingham, Alabama • Long Beach, California • Mission Viejo, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 23, 2026, 9:24 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Skin Characteristics of Parents of Food Allergic Pediatric Patients

NCT04198753
View directory record Official record
Conditions
Food Allergy in Children
Interventions
Skin tape stripping, Skin barrier assessment, Blood draw
Diagnostic Test · Device
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced Sep 23, 2026, 9:24 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy

NCT07287033
View directory record Official record
Conditions
Peanut Allergies
Interventions
MY006 Low Dose, MY006 Mid Dose, MY006 High Dose, MY006 Selected Dose, Placebo (Vehicle)
Drug
Lead sponsor
Mabylon AG
Industry
Eligibility
12 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
9
States / cities
Little Rock, Arkansas • Aurora, Colorado • Colorado Springs, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 23, 2026, 9:24 PM EDT
Completed Not applicable Interventional Results available

Oral Peanut Immunotherapy

NCT01324401
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut flour OIT
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Sep 23, 2026, 9:24 PM EDT
Recruiting Phase 2 Interventional

Efficacy of Tezepelumab in Peanut Oral Immunotherapy

NCT07015996
View directory record Official record
Conditions
Peanut Allergy
Interventions
Tezepelumab, Peanut Oral Immunotherapy (OIT), Placebo for Tezepelumab
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
10
States / cities
Little Rock, Arkansas • Los Angeles, California • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 23, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization

NCT03736447
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101 powder provided in capsules & sachets, Placebo powder provided in capsules & sachets
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
1 Year to 3 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Little Rock, Arkansas • Mountain View, California • Rolling Hills Estates, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Sep 23, 2026, 9:24 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Impact of Vaccination on Th2 Immunity in Infancy

NCT02213341
View directory record Official record
Conditions
Food Hypersensitivity
Interventions
Skin prick allergen test, Blood draw
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Months to 7 Months
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 23, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)

NCT02635776
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101 powder provided in capsules & sachets, Placebo powder provided in capsules & sachets
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
49
States / cities
Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Sep 23, 2026, 9:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Wheat Germ Supplementation Will Improve Markers of Gut Health, Inflammation, and Insulin Resistance in Overweight Adults

NCT03989882
View directory record Official record
Conditions
Overweight, Insulin Resistance, Inflammation
Interventions
Wheat germ energy ball, Control
Other
Lead sponsor
Oklahoma State University
Other
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Stillwater, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Sep 23, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

NCT03881696
View directory record Official record
Conditions
Peanut Allergy, Multi-food Allergy
Interventions
Omalizumab, Placebo for Omalizumab, Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen Oral Immunotherapy, Double-Blind Placebo-Controlled Food Challenge Based Treatment
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 55 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
10
States / cities
Little Rock, Arkansas • Stanford, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 23, 2026, 9:24 PM EDT
Completed Phase 2 Interventional Results available

Mechanisms of Desensitization During Peanut Oral Immunotherapy

NCT01814241
View directory record Official record
Conditions
Food Hypersensitivity
Interventions
Open label peanut OIT
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
4 Years to 12 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Sep 23, 2026, 9:24 PM EDT